PSD4

Across TCGA pan-cancer cohorts, PSD4 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated PSD4 data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher PSD4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PSD4 expression acts as an unfavorable survival marker.

BLCA, LGG, and HNSC are the cancer types where PSD4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	III,IV	0.217	0.578	.002	42	view →
LGG	OS	Median	All	0.194	0.830	<.001	12	view →
HNSC	OS	Median	III,IV	0.079	0.746	<.001	12	view →
SARC	OS	Median	All	0.238	0.826	.001	11	view →
COAD	DFS	Median	All	0.436	0.795	.011	7	view →
SCLC	OS	Median	All	0.347	0.660	.029	6	view →
PRAD	DFS	Median	All	0.617	0.886	.020	6	view →
LIHC	OS	Median	II,III,IV	0.239	0.715	.035	6	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

PSD4–BLCA (DFS)

Open the BLCA breakdown →